WallStSmart

CoStar Group Inc (CSGP)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CoStar Group Inc generates 62823% more annual revenue ($3.25B vs $5.16M). EUDA leads profitability with a 5.2% profit margin vs 0.2%. EUDA trades at a lower P/E of 0.9x. CSGP earns a higher WallStSmart Score of 50/100 (D+).

CSGP

Hold

50

out of 100

Grade: D+

Growth: 6.0Profit: 4.0Value: 4.7Quality: 7.3
Piotroski: 2/9Altman Z: 3.95

EUDA

Hold

36

out of 100

Grade: F

Growth: 5.3Profit: 3.0Value: 8.3Quality: 4.5
Piotroski: 2/9Altman Z: -74.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CSGPSignificantly Overvalued (-34092.9%)

Margin of Safety

-34092.9%

Fair Value

$0.14

Current Price

$41.41

$41.27 premium

UndervaluedFair: $0.14Overvalued
EUDAUndervalued (+68.0%)

Margin of Safety

+68.0%

Fair Value

$2.72

Current Price

$11.47

$8.75 discount

UndervaluedFair: $2.72Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CSGP4 strengths · Avg: 9.0/10
PEG RatioValuation
0.1810/10

Growing faster than its price suggests

Altman Z-ScoreHealth
3.9510/10

Safe zone — low bankruptcy risk

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
26.9%8/10

Revenue surging 26.9% year-over-year

EUDA3 strengths · Avg: 10.0/10
P/E RatioValuation
0.9x10/10

Attractively priced relative to earnings

Revenue GrowthGrowth
60.2%10/10

Revenue surging 60.2% year-over-year

Debt/EquityHealth
-0.6210/10

Conservative balance sheet, low leverage

Areas to Watch

CSGP4 concerns · Avg: 2.8/10
Return on EquityProfitability
0.1%3/10

ROE of 0.1% — below average capital efficiency

Profit MarginProfitability
0.2%3/10

0.2% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
2070.5x2/10

Premium valuation, high expectations priced in

EUDA4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$692,0703/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
5.2%3/10

5.2% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : CSGP

The strongest argument for CSGP centers on PEG Ratio, Altman Z-Score, Price/Book. Revenue growth of 26.9% demonstrates continued momentum. PEG of 0.18 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on P/E Ratio, Revenue Growth, Debt/Equity. Revenue growth of 60.2% demonstrates continued momentum.

Bear Case : CSGP

The primary concerns for CSGP are Return on Equity, Profit Margin, Piotroski F-Score. A P/E of 2070.5x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

CSGP profiles as a growth stock while EUDA is a hypergrowth play — different risk/reward profiles.

CSGP carries more volatility with a beta of 0.90 — expect wider price swings.

EUDA is growing revenue faster at 60.2% — sustainability is the question.

EUDA generates stronger free cash flow (-619,323), providing more financial flexibility.

Bottom Line

CSGP scores higher overall (50/100 vs 36/100) and 26.9% revenue growth. EUDA offers better value entry with a 68.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CoStar Group Inc

REAL ESTATE · REAL ESTATE SERVICES · USA

CoStar Group, Inc. provides online market information, analysis and services to the commercial real estate, hospitality, residential and related professional industries in the United States, Canada, Europe, Asia Pacific and Latin America. The company is headquartered in Washington, the District of Columbia.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. Utilizing advanced technologies and a dynamic pipeline, the company aims to tackle critical challenges in supportive care and immune modulation. With a strong emphasis on research and development, EUDA is well-positioned to lead healthcare innovation, committed to improving patient outcomes and expanding access to vital medical therapies through its promising clinical programs.

Visit Website →

Want to dig deeper into these stocks?